Compounds > aceclidine
Page last updated: 2024-12-04

aceclidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aceclidine: was heading 1975-94; use QUINUCLIDINES to search ACECLIDINE 1975-94; cholinomimetic used to reduce intraocular pressure in glaucoma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1979
CHEMBL ID20835
CHEBI ID93847
SCHEMBL ID121393
MeSH IDM0224858
PubMed CID10031478
CHEMBL ID487297
SCHEMBL ID14665337
MeSH IDM0224858

Synonyms (108)

Synonym
aceclidina [inn-spanish]
3-quinuclidinol acetate
einecs 212-574-1
1-azabicyclo(2.2.2)octan-3-ol, acetate
glaucostat
aceclidinum [inn-latin]
aceclidine [usan:inn]
1-azabicyclo(2.2.2)octan-3-ol, acetate (ester)
3-quinuclidinol acetate (ester)
al 304
aceclidina
unii-0578k3elio
0578k3elio ,
aceclidinum
nsc 657843
acetic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester
aceclidine,s(+)
acetic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester(aceclidine)
bdbm50034625
aceclidine,r(-)
BRD-A32673558-003-02-1
DIVK1C_000180
KBIO1_000180
NCI60_020173
NCI60_020184
3-acetoxyquinuclidine
nsc657843
nsc-657843
glaucostat (tn)
827-61-2
D02750
aceclidine (usan/inn)
quinuclidin-3-yl acetate
1-azabicyclo[2.2.2]octan-3-ol, acetate (ester)
3-quinuclidinol, acetate (ester)
aceclidine
SPECTRUM_001338
SPECTRUM5_001301
IDI1_000180
BSPBIO_002911
NCGC00024733-02
KBIO2_006954
KBIOSS_001818
KBIOGR_000742
KBIO2_001818
KBIO2_004386
KBIO3_002411
SPBIO_001110
SPECTRUM3_001446
SPECTRUM4_000421
SPECTRUM2_001235
NINDS_000180
NCGC00024733-03
L023942
nsc-758239
CHEMBL20835 ,
3-quinuclidinol dl-form acetate (ester)
1-azabicyclo[2.2.2]octan-3-yl acetate
A840430
NCGC00024733-04
HMS3264B20
AKOS006281409
nsc758239
pharmakon1600-01501124
cas-827-61-2
tox21_110921
dtxsid2045658 ,
dtxcid0025658
FT-0607358
BRD-A80567352-003-01-6
aceclidine [who-dd]
aceclidine [usan]
aceclidine [inn]
aceclidine [mart.]
3-quinuclidinol dl-form acetate (ester) [mi]
CCG-212926
CS-B0278
SCHEMBL121393
(+) 3-acetoxy quinuclidine
(rs) 3-acetoxy quinuclidine
(rs)-3-acetoxyquinuclidine
1-azabicyclo[2.2.2]oct-3-yl acetate
STL430459
3-quinuclidinol, acetate
1-azabicyclo[2.2.2]oct-3-yl acetate #
1-azabicyclo[2.2.2]octan-3-ol, acetate
3-quinuclidinyl acetate
acetic acid quinuclidin-3-yl ester
AB00053601_02
AB00053601_03
mfcd00468105
CHEBI:93847
acetic acid 1-azabicyclo[2.2.2]octan-3-yl ester
quinuclidin-3-ylacetate
DS-5025
SY111901
DB13262
Q2362603
BRD-A32673558-001-01-7
EN300-3463436
HY-32067
[(1s)-1-[(6-aminopurin-9-yl)methyl]-2-hydroxy-ethoxy]methyl-(2-octadecoxyethoxy)phosphinic acid
ode-hpmpa
1-octadecyloxyethyl-(s)-hpmpa
ode-(s)-hpmpa
CHEMBL487297
SCHEMBL14665337
[(2s)-1-(6-aminopurin-9-yl)-3-hydroxypropan-2-yl]oxymethyl-(2-octadecoxyethoxy)phosphinic acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
" However, the ether lipid esters of (S)-HPMPA, hexadecyloxypropyl-[(S)-HPMPA] [HDP-(S)-HPMPA] and octadecyloxyethyl-[(S)-HPMPA] [ODE-(S)-HPMPA], had significantly enhanced activity in vitro and are orally bioavailable in mice."( Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
Beadle, JR; Collins, DJ; Herrod, BP; Hostetler, KY; Keith, KA; Kern, ER; Quenelle, DC; Trahan, J, 2007)		0.34
" HDP-(S)-HPMPA is orally bioavailable and provides excellent liver exposure to the drug."( Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.
Beadle, JR; Hostetler, KY; Korba, BE; Morrey, JD; Wyles, DL, 2009)		0.35

Dosage Studied

ExcerptRelevanceReference
" Oxotremorine generated dose-response curves that were similar in both the circular and longitudinal vectors and intermediate to those previously reported for carbachol and aceclidine."( The effect of muscarinic agonists and selective receptor subtype antagonists on the contractile response of the isolated rhesus monkey ciliary muscle.
Gabelt, BT; Kaufman, PL; Poyer, JF, 1994)		0.48
" Dose-response curves for steady-state pupil size and for behavioral phase shifts were constructed for 3 pupil conditions (dilated, constricted, and control)."( Photic sensitivity ranges of hamster pupillary and circadian phase responses do not overlap.
Cooper, HM; Hut, RA; Oklejewicz, M; Rieux, C, 2008)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinuclidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency0.04230.531815.435837.6858AID504845
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency3.61250.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)0.51000.00052.773925.1700AID104017
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki8.26000.00010.579710.0000AID142348
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)0.51000.00052.891925.1700AID104017
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki8.26000.00011.48339.1400AID142348
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)0.51000.00052.747825.1700AID104017
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki8.26000.00010.68688.2600AID142348
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)0.51000.00052.780225.1700AID104017
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki8.26000.00010.66618.2600AID142348
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)0.51000.00053.314249.5000AID104017
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki8.26000.00010.58908.2600AID142348
Muscarinic acetylcholine receptor DM1Drosophila melanogaster (fruit fly)Ki122.00000.00051.42495.2000AID1090601; AID1090602
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M1Homo sapiens (human)EC50 (µMol)4.46600.00161.304310.0000AID141971
Muscarinic acetylcholine receptor M3Mus musculus (house mouse)EC50 (µMol)10.00009.90009.950010.0000AID141597
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (108)

Assay IDTitleYearJournalArticle
AID141452Binding affinity for muscarinic acetylcholine receptor M1 using [3H]oxotremorine-M (Oxo-M) radioligand in rat hippocampus membranes1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.
AID175669Effective concentration of compound that can stimulate phosphoinositol metabolism in rat hippocampus1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID1090601Displacement of [3H]QNB from Drosophila melanogaster mAChR by scintillation counting2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID142348Binding affinity against muscarinic acetylcholine receptor from rat brain crude membrane, using [3H]-NMS (N-Methylscopolamine) as the radioligand.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
In vitro muscarinic activity of spiromuscarones and related analogs.
AID197273Maximum stimulation of phosphatidyl inositol in rat hippocampal tissue, activity is expressed as percent of carbachol response1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
In vitro muscarinic activity of spiromuscarones and related analogs.
AID1090595Toxicity to Musca domestica (house fly) assessed as mortality at 25 ug/fly measured after 2.5 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID180116Inhibition of the response (stimulation of phosphoinositol metabolism in rat hippocampus) to 10 uM of compound by AF-DX 1161993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID180118Inhibition of the response (stimulation of phosphoinositol metabolism in rat hippocampus) to 10 uM of compound by pirenzepine1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID104017Inhibition of [3H]-(R)-QNB binding to muscarinic receptors of rat brain membranes.1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID141978Maximum stimulation of phosphoinositol (PI) hydrolysis in the A9 L cell line transfected with the muscarinic acetylcholine receptor M1 at 100 uM1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.
AID230727Ratio of the Ki (NMS) value to that of Ki (Oxo-M).1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
In vitro muscarinic activity of spiromuscarones and related analogs.
AID1090593Toxicity to Musca domestica (house fly) assessed as mortality at 75 ug/fly measured after 0.5 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID180117Inhibition of the response (stimulation of phosphoinositol metabolism in rat hippocampus) to 10 uM of compound by p-F-hexahydrosiladifenidol1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID1090597Toxicity to Musca domestica (house fly) assessed as mortality at 25 ug/fly measured after 1 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID141971Effective concentration required for stimulation of phosphoinositol (PI) hydrolysis in the A9 L cell line transfected with the Muscarinic acetylcholine receptor M1.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.
AID1090589Toxicity to Musca domestica (house fly) assessed as mortality at 75 ug/fly measured after 24 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID119570Compound at an intraperitoneal dose of 10 mg/Kg was tested for salivation in mice expressed as score; 2=Marked salivation or tremor1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.
AID1090591Toxicity to Musca domestica (house fly) assessed as mortality at 75 ug/fly measured after 1.5 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID142488Inhibition of specific [3H](R)-QNB binding to Muscarinic acetylcholine receptor in rat brain membranes1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID1090592Toxicity to Musca domestica (house fly) assessed as mortality at 75 ug/fly measured after 1 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID142349Binding affinity against muscarinic acetylcholine receptor from rat brain crude membrane, using [3H]OXO-M (oxotremorine) as the radioligand.1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
In vitro muscarinic activity of spiromuscarones and related analogs.
AID141451Binding affinity for muscarinic acetylcholine receptor M1 using [3H]pirenzepine (Pz) radioligand in rat hippocampus membranes.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.
AID1090594Toxicity to Musca domestica (house fly) assessed as mortality at 25 ug/fly measured after 24 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID1090598Toxicity to Musca domestica (house fly) assessed as mortality at 25 ug/fly measured after 0.5 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID1090590Toxicity to Musca domestica (house fly) assessed as mortality at 75 ug/fly measured after 2.5 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID186265Ability to stimulate phosphoinisitol metabolism was examined in the rat hippocampus1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID189455Ability to stimulate phosphoinositol metabolism was examined in the rat cerebral cortex at 100 uM1993Journal of medicinal chemistry, Apr-02, Volume: 36, Issue:7
Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
AID141597Tested against Muscarinic acetylcholine receptor M3 expressed in A9 L cell line1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID141602Maximum stimulation at Muscarinic acetylcholine receptor M3 expressed in A9 L cells1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID1090602Displacement of [3H]AF-DX 384 from Drosophila melanogaster mAChR by scintillation counting2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID196226Tested for agonist activity through assays of phosphoinositide (PI) metabolism in slices from rat cerebral cortex1997Journal of medicinal chemistry, Apr-11, Volume: 40, Issue:8
Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
AID1090596Toxicity to Musca domestica (house fly) assessed as mortality at 25 ug/fly measured after 1.5 hr2007Journal of agricultural and food chemistry, Mar-21, Volume: 55, Issue:6
Insect muscarinic acetylcholine receptor: pharmacological and toxicological profiles of antagonists and agonists.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID373253Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mean death day at 3 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373442Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373246Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as log reduction of viral titer per gram of liver at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373415Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mortality at 10 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373416Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mortality at 30 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373441Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373403Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mean death day at 10 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID556388Cytotoxicity against human Huh7.5 cells administered for 3 days measured 24 hrs after last dose by neutral red dye uptake assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.
AID560900Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as decrease in extracellular viral DNA level after 24 hrs by blot hybridization assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.
AID556387Antiviral activity against HCV2A SGR-JFH-1 infected in human Huh7.5 cells assessed as decrease in intracellular viral RNA treated for 3 days measured 24 hrs after last dose by luciferase reporter gene-based blot hybridization2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.
AID556390Selectivity index, ratio of CC50 for human Huh7.5 cells to EC50 for HCV genotype 2A SGR-JFH-1 infected in human Huh7.5 cells2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.
AID373243Toxicity in Vaccinia virus WR infected BALB/c mouse assessed as survival at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373407Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mean death day at 30 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373255Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mean death day at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373447Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as log reduction of viral titer per gram of liver at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373409Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mean death day at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID563683Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 25 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID373444Selectivity index, ratio of CC50 for HFF cells to EC50 for Vaccinia virus Copenhagen2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID556386Antiviral activity against HCV1B BM4-5 infected in human Huh7.5 cells assessed as decrease in intracellular viral RNA treated for 3 days measured 24 hrs after last dose by luciferase reporter gene-based blot hybridization2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.
AID373405Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mean death day at 3 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373254Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mean death day at 10 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID520605Cytotoxicity against human WI38 cells by neutral red assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Anti-BK virus activity of nucleoside analogs.
AID373443Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373248Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mean death day at 10 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373448Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as log reduction of viral titer per gram of spleen at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID563685Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 5 uM treated for overnight followed by drug washout measured on day 52009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID373450Toxicity in Cowpox virus Brighton infected BALB/c mouse assessed as survival at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID560901Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.
AID373445Cytotoxicity against HFF cells after 7 days2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID560964Antiviral activity against HBV infected in transgenic mouse assessed as decrease in liver viral DNA level at 4 mg/kg, po administered daily for 14 days measured post last dose2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.
AID373439Selectivity index, ratio of CC50 for HFF cells to EC50 for Cowpox virus Brighton2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID563684Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 12.5 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID373258Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mortality at 30 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373250Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mean death day at 3 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373245Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as log reduction of viral titer per gram of spleen at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373419Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mortality at 10 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373402Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mean death day at 3 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373406Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mean death day at 10 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373393Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mortality at 30 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373408Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mean death day at 3 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID520606Selectivity index, ratio of CC50 for human WI38 cells to EC50 for BK polyomavirus ATCC VR8372008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Anti-BK virus activity of nucleoside analogs.
AID373244Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as log reduction of viral titer per gram of kidney at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373414Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mortality at 3 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373411Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mortality at 10 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID563681Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 75 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID563686Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality treated for overnight followed by drug washout measured on day 52009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID373261Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mortality at 10 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373397Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mortality at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID563682Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 50 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID563680Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 100 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID520604Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Anti-BK virus activity of nucleoside analogs.
AID373395Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mortality at 3 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373251Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mean death day at 10 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID556389Selectivity index, ratio of CC50 for human Huh7.5 cells to EC50 for HCV genotype 1B BM4-5 infected in human Huh7.5 cells2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons.
AID373252Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mean death day at 30 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID560902Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to EC50 for HBV infected in human HepG2(2.2.15) cells2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.
AID373451Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as reduction of virus titer in lung at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373260Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mortality at 3 mg/kg, po treated for 5 days after 48 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373257Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mortality at 10 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373449Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as log reduction of viral titer per gram of kidney at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373412Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mortality at 30 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373452Toxicity in BALB/c mouse at 30 mg/kg, po2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373256Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mortality at 3 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373420Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mortality at 30 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373247Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mean death day at 3 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373404Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mean death day at 30 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373418Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mortality at 3 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373440Selectivity index, ratio of CC50 for HFF cells to EC50 for Vaccinia virus WR2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373396Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mortality at 10 mg/kg, po treated for 5 days after 24 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373249Antiviral activity against Cowpox virus Brighton infected BALB/c mouse assessed as mean death day at 30 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
AID373410Antiviral activity against Vaccinia virus WR infected BALB/c mouse assessed as mortality at 3 mg/kg, po treated for 5 days after 72 hrs of viral inoculation2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.94)18.7374
1990's13 (38.24)18.2507
2000's15 (44.12)29.6817
2010's4 (11.76)24.3611
2020's1 (2.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.40 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.67 (4.65)
Search Engine Demand Index51.48 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (38.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.13%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other31 (96.88%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia [NCT03201562]Phase 258 participants (Actual)Interventional2017-04-30Completed
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine + Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia [NCT05431543]Phase 258 participants (Actual)Interventional2022-08-06Completed
Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic Subjects [NCT05753189]Phase 3361 participants (Actual)Interventional2023-02-21Active, not recruiting
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia [NCT05656027]Phase 3469 participants (Actual)Interventional2022-12-19Active, not recruiting
A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia [NCT05936489]Phase 130 participants (Actual)Interventional2023-07-06Completed
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia [NCT05728944]Phase 3229 participants (Actual)Interventional2023-04-24Active, not recruiting
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia [NCT06045299]Phase 3300 participants (Anticipated)Interventional2023-09-27Recruiting
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine /Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia [NCT05294328]Phase 262 participants (Actual)Interventional2022-05-05Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03201562 (1) [back to overview]Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye

Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye

Proportion of subjects with at least a 3 line (15 letter) improvement in near visual acuity in the study eye at 1 hour post-treatment in the mITT population (NCT03201562)
Timeframe: 1 hour post-treatment

Interventionpercentage of participants (Number)
Aceclidine+Tropicamide Combination47.22
Aceclidine47.22
Vehicle2.38

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-diphenylacetoxy-1,1-dimethylpiperidinium
4-diphenylacetoxy-1,1-dimethylpiperidinium: muscarinic receptor antagonist; RN given refers to parent cpd; do not confuse abbreviation 4-DAMP with a similar cpd which does not contain dimethyl groups. 4-DAMP(1+) : A quaternary ammonium salt obtained by formal methylation of the tertiary amino function of 4-diphenylacetoxy-N-methylpiperidine.		2.3920quaternary ammonium ioncholinergic antagonist;
muscarinic antagonist
tacrine
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.		1.9910acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
1-methyl-3,6-dihydro-2H-pyridine-5-carboxylic acid prop-2-ynyl ester
[no description available]		2.0310dihydropyridine
arecoline
Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.. arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.		2.6830enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine		metabolite;
muscarinic agonist
dichlorvos
Dichlorvos: An organophosphorus insecticide that inhibits ACETYLCHOLINESTERASE.. dichlorvos : An alkenyl phosphate that is the 2,2-dichloroethenyl ester of dimethyl phosphate.		2.0510alkenyl phosphate;
dialkyl phosphate;
organochlorine acaricide;
organophosphate insecticide		anthelminthic drug;
antibacterial agent;
antifungal agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor
isoproterenol
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.		2.0310catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
oxotremorine m
oxotremorine M: structure given in first source		2.0310quaternary ammonium ionmuscarinic agonist
oxotremorine
Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.		2.9240N-alkylpyrrolidine
pirenzepine
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.		2.9240pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
tropicamide
Tropicamide: One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.		2.0410acetamides
carbachol
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.		3.3870ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
pilocarpine
Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.		8.6190pilocarpineantiglaucoma drug
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride
(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride: A drug that selectively activates certain subclasses of muscarinic receptors and also activates postganglionic nicotinic receptors. It is commonly used experimentally to distinguish muscarinic receptor subtypes.		2.0310
physostigmine
Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.		1.9910carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		2.4520mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
quinuclidines
Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.		5.78211quinuclidines;
saturated organic heterobicyclic parent
paraoxon
[no description available]		2.0310aryl dialkyl phosphate;
organophosphate insecticide		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
mouse metabolite
o,o-diethyl o-3,5,6-trichloro-2-pyridyl phosphate
[no description available]		2.0310
quinuclidinyl benzilate
[no description available]		2.0310
timolol
(S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.		6.9910timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
colforsin
Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.		2.4120acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
xanomeline
xanomeline: a cholinergic agonist; used in the treatment of Alzheimer's disease; structure given in first source		2.6930tetrahydropyridine;
thiadiazoles		muscarinic agonist;
serotonergic agonist
armin
Armin: A reversible organophosphorus cholinesterase inhibitor. It also affects the presynaptic membrane and inhibits membrane postsynaptic cholinergic receptors. The compound had former use as a miotic.		1.9810organic phosphonate;
phosphonic ester
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.45201,2,3-triazole
nicotine
(S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.		2.07103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
methoctramine
methoctramine tetrahydrochloride : A hydrochloride obtained by combining methoctramine with four molar equivalents of hydrochloric acid.. methoctramine : A tetramine that is N,N'-bis(6-aminohexyl)octane-1,8-diamine where the primary amino groups both carry 2-methoxybenzyl substituents.. methoctramine: structure given in first source		2.0310hydrochloridemuscarinic antagonist
afdx 116
otenzepad: cardioselective muscarinic receptor antagonist; structure given in first source		2.9240benzodiazepine
afdx 384
AF-DX 384 : A pyridobenzodiazepine that acts as a selective antagonist of the muscarinic acetylcholine receptors.		2.0310benzodiazepine
pd 142505-0028
[no description available]		1.9910
atropine
tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.		210
lu 25-109
LU 25-109-T: partial muscarinic M1 agonist and presynaptic M2 autoreceptor antagonist		1.9910dihydropyridine
dihydropyridines
Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.		1.9910
methylatropine nitrate
[no description available]		2.0310
4-diphenylacetoxy-n-methylpiperidine methiodide
4-DAMP methiodide : A quaternary ammonium salt obtained by combining equimolar amounts of 4-diphenylacetoxy-N-methylpiperidine and iodomethane.		2.0310iodide salt;
quaternary ammonium salt		cholinergic antagonist;
muscarinic antagonist
lithium
Lithium: An element in the alkali metals family. It has the atomic symbol Li, atomic number 3, and atomic weight [6.938; 6.997]. Salts of lithium are used in treating BIPOLAR DISORDER.		1.9910alkali metal atom
dapiprazole
[no description available]		7.4520N-alkylpiperazine;
N-arylpiperazine;
pyridines		alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug
cytochalasin b
Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.		1.9910cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
talsaclidine fumarate
talsaclidine fumarate: selectively activate M1 receptors in sympathetic ganglia; may be useful in cholinergic substitution therapy of Alzheimer's disease		1.9910
milameline
milameline: a candidate drug for the treatment of age-related disorders of cognition; RN refers to the E-isomer; structure given in first source		1.9910
sabcomeline
sabcomeline: selective for M1 receptors; RN refers to (R,S)-isomer; structure in first source		1.9910quinuclidines
brimonidine tartrate
Brimonidine Tartrate: A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.		7.4520
scopolamine hydrobromide
[no description available]		1.9910
piperidines
Piperidines: A family of hexahydropyridines.		2.6930
imidacloprid
(E)-imidacloprid : The E-isomer of imidacloprid.		2.0310imidacloprid;
imidazolidines;
monochloropyridine		environmental contaminant;
genotoxin;
neonicotinoid insectide;
nicotinic acetylcholine receptor agonist;
xenobiotic
muramidase
Muramidase: A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17.		1.9810
brl 42810
[no description available]		2.04102-aminopurines;
acetate ester		antiviral drug;
prodrug
praziquantel
azinox: Russian drug		2.0510isoquinolines
stavudine
stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase. Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.		2.0410dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
zidovudine
zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.. Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.		2.0410azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
adefovir
adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.. adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).		2.04106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
cidofovir anhydrous
Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.		2.0310phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
lamivudine
[no description available]		2.4520monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
adefovir dipivoxil
bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.		2.45206-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
9-(s)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine
[no description available]		2.9640
cmx 001
[no description available]		2.0310
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		2.0410purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
cyclopropavir
cyclopropavir: cyclopropavir is the (Z)-isomer; has antiviral activity; structure in first source		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Blood Poisoning
[description not available]		02.0710
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.0710
Intraocular Pressure
The pressure of the fluids in the eye.		03.821
Disease
A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.		01.9310
Urination Disorders
Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.		01.9310
Intestinal Diseases
Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.		01.9310
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.4120
Night Blindness
Failure or imperfection of vision at night or in dim light, with good vision only on bright days. (Dorland, 27th ed)		03.4111
E coli Infections
[description not available]		01.9810
Primary Peritonitis
[description not available]		01.9810
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		01.9810
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		01.9810
Amnesia-Memory Loss
[description not available]		01.9910
Amnesia
Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)		06.9910
Hypothermia, Accidental
[description not available]		01.9910
Action Tremor
[description not available]		01.9910
Hypothermia
Lower than normal body temperature, especially in warm-blooded animals.		01.9910
Tremor
Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.		01.9910
Cow Pox
[description not available]		02.0310
Bilharziasis
[description not available]		02.0510
Schistosomiasis
Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.		02.0510